The global vulvovaginal candidiasis treatment market size is expected to reach USD 1.64 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.39% from 2022 to 2030. The increasing disease burden of VVC, approval of novel drugs with the ability to address the unmet needs, and efforts by government & non-profit organizations to increase awareness are among the key factors augmenting the industry growth. According to the NCBI article, globally, around 75% of women suffer from this disease once in their life.Vulvovaginal candidiasis is the second most common infection in women, affecting around 138 million women globally.
About 10-20% of women report complicated disease conditions, which are increasing annually. Moreover, the NCBI article reports an upsurge in recurrent infection incidences. Thus, the rising prevalence of the disease is boosting the treatment demand, thereby driving industry growth.Azoles, such as fluconazole, are indicated as the first line of treatment and held a significant share of the market, however, in recent years, there has been a surge in azole resistance cases, which led to rising in recurring disease cases. However, novel drugs, such as VIVJOA and BREXAFEMME, are effectiveagainst recurring VVC. In addition, the presence of over-the-counter intravaginal agents, which enables easy patient treatment access, supports the market growth.
This includes products, such as miconazole cream, clotrimazole cream, and tioconazole ointment. They are indicated to treat mild to moderate conditions and are used as maintenance therapy. The industry is saturated with generic products, which could slow down growth. However, key players, such as Mycovia Pharmaceuticals and SCYNEXIS, Inc., are engaged in strategic initiatives like new product development and launches, which are anticipated to propel the market growth over the forecast period. For instance, in July 2022, Mycovia Pharmaceuticals launched VIVJOA for recurrent VVC. The company has already received VIVJOA approval in Asian, European, and Latin American countries. In September 2021, SCYNEXIS, Inc. launched BREXAFEMME in the U.S., the first oral non-azole therapeutic indicated for VVC.
Request a free sample copy or view report summary: Vulvovaginal Candidiasis Treatment Market Report
In 2021, the fluconazole segment accounted for the largest share owing to its high prescription rate and the non-availability of other drugs with similar efficacy
The topical segment is estimated to grow at a steady CAGR during the forecast period due to the presence of OTC and prescription formulations, such as azole creams and ointments
Based on distribution channel, the retail pharmacy segment dominated the industry in 2021 due to the ease of availability and the presence of OTCs drugs
Asia Pacific is anticipated to experience the fastest CAGR over the forecast period due to increased awareness among the population, rise in disposable income, and high prevalence of VVC in developing countries
Grand View Research has segmented the global vulvovaginal candidiasis treatment market on the basis of drug class, route of administration, distribution channel, and region:
Vulvovaginal Candidiasis Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
Vulvovaginal Candidiasis Treatment Route of Administration Outlook (Revenue, USD Million; 2018 - 2030)
Vulvovaginal Candidiasis Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Vulvovaginal Candidiasis Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
List of Key Players of Vulvovaginal Candidiasis Treatment Market
Astellas Pharma Inc.
Mycovia Pharmaceuticals, Inc.
Basilea Pharmaceutica Ltd.
Grupo Ferrer Internacional S.A.
Bristol-Myers Squibb Company
GET A FREE SAMPLE
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
"The quality of research they have done for us has been excellent..."